TCG Crossover Management’s Centessa Pharmaceuticals CNTA Stock Holding History

TCG Crossover Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,286,480	Closed	-$170M	–	55
2026 Q1	$170M	Hold	4,286,480	–	–	4.87%	5
2025 Q4	$107M	Buy	4,286,480 +1,150,000	+37%	+$29.1M	3.55%	5
2025 Q3	$76.1M	Buy	3,136,480 +245,664	+8%	+$4.37M	3.74%	5
2025 Q2	$38M	Hold	2,890,816	–	–	4.34%	8
2025 Q1	$41.6M	Hold	2,890,816	–	–	5.67%	3
2024 Q4	$48.4M	Hold	2,890,816	–	–	4.73%	5
2024 Q3	$46.2M	Hold	2,890,816	–	–	3.92%	13
2024 Q2	$26.1M	Buy	2,890,816 +850,000	+42%	+$8.06M	2.72%	15
2024 Q1	$23.1M	Hold	2,040,816	–	–	1.82%	23
2023 Q4	$16.2M	Hold	2,040,816	–	–	1.8%	20
2023 Q3	$13.2M	Buy	+2,040,816	New	+$14M	1.94%	19

TCG Crossover Management's CNTA Position: Q2 2026 in Review

TCG Crossover Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 4,286,480 shares — an estimated $170M sold.

TCG Crossover Management first reported a position in CNTA in Q3 2023 and held it in 11 quarters. The position peaked at $170M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

TCG Crossover Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
TCG Crossover Management sold 4,286,480 Centessa Pharmaceuticals shares in Q2 2026, an estimated $170M.
TCG Crossover Management first reported a position in Centessa Pharmaceuticals in Q3 2023 and held it in 11 quarters.
TCG Crossover Management's Centessa Pharmaceuticals position peaked at $170M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.